Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Shares Outstanding (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Shares Outstanding for 4 consecutive years, with $86.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding rose 2.08% to $86.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $86.5 million, a 2.08% increase, with the full-year FY2024 number at $85.8 million, up 42.26% from a year prior.
  • Shares Outstanding was $86.5 million for Q3 2025 at Century Therapeutics, roughly flat from $86.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $86.5 million in Q3 2025 to a low of $57.6 million in Q1 2022.
  • A 4-year average of $70.0 million and a median of $60.3 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: skyrocketed 42.56% in 2024, then rose 2.08% in 2025.
  • Century Therapeutics' Shares Outstanding stood at $58.5 million in 2022, then increased by 3.18% to $60.3 million in 2023, then surged by 42.26% to $85.8 million in 2024, then rose by 0.81% to $86.5 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Shares Outstanding are $86.5 million (Q3 2025), $86.3 million (Q2 2025), and $86.1 million (Q1 2025).